Heron Therapeutics | HRTX - Current Liabilities

Stock Price
0.80
Daily Change
0.03 4.31%
Monthly
-33.50%
Yearly
-65.15%
Q1 Forecast
0.76

Heron Therapeutics reported $96.1M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
ALKERMES USD 543.44M 69.08M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 194.46M 12.23M Dec/2025
ANI Pharmaceuticals USD 278.11M 7.56M Dec/2025
Anika Therapeutics USD 21.91M 2.82M Dec/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
Eisai JPY 387.67B 9.42B Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Ligand Pharmaceuticals USD 37.45M 6.91M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 120.59M 13.51M Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Surmodics USD 20.54M 347K Sep/2024
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Veracyte USD 59.94M 12.22M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025